Chicago Atlantic Real Estate Finance, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The company was formed March 30, 2021 and commenced operations April 1; results cover inception through year-end, so there is no prior comparable period.
Business context
Chicago Atlantic is an externally managed commercial real estate finance company focused primarily on senior loans to state-licensed cannabis operators and property owners. Loans are generally secured by real estate and, where permitted, other borrower assets. The company intends to qualify as a REIT and relies on an Investment Company Act exemption.
Financial and portfolio highlights
| Metric | 2021 / December 31, 2021 |
|---|---|
| Revenue | $11.1 million: $10.7 million interest income and $0.3 million prepayment fee income |
| Net income | $9.5 million; basic and diluted earnings per share were $1.47 |
| Distributable earnings | $9.7 million; adjusted distributable earnings were $9.9 million, or $1.54 per weighted-average share. These are non-GAAP measures. |
| Cash flows | Audited cash flow statement reports $6.7 million from operations, $145.2 million used in investing, and $218.8 million from financing. The MD&A cash-flow discussion gives a different operating-cash-flow figure ($5.7 million); see investor verification items. |
| Assets and liquidity | Total assets $278.2 million, including $80.2 million unrestricted cash and $196.9 million net loans. Stockholders’ equity was $264.1 million; total liabilities were $14.1 million. |
| Loans | 21 loans to 21 borrowers; $200.6 million principal outstanding, $197.0 million carrying value before the $0.1 million credit-loss allowance, and $235.1 million total commitments, including $34.7 million undrawn. Weighted-average stated remaining life was 2.2 years; weighted-average YTM IRR was 18.6%. |
| Credit and collateral | All loans were current and none were on non-accrual; no borrower defaults were reported. The CECL allowance was $147,949, including $13,407 for unfunded commitments. The company reported 47.6% of loans backed by personal or corporate guarantees. |
| Debt and financing | No borrowings were outstanding under the revolving facility at year-end. Its commitment was increased to $45 million in December 2021; it is subject to financial covenants. |
| Distributions | Declared $1.06 per share across the reported 2021 distribution periods, including $0.26 for Q4, paid January 2022. The filing cautions that past distributions do not assure future payments. |
Material changes and unusual items
- The company completed its IPO in December 2021, selling 6.25 million shares at $16 per share and raising approximately $92.9 million net; it also completed a $7.5 million concurrent private placement. The underwriters exercised part of the over-allotment in January 2022, generating additional net proceeds of about $4.5 million.
- By year-end, the company had deployed substantial capital into loan originations and advances. It reported approximately $174.4 million of new loan principal funded during the period, in addition to approximately $40.2 million contributed from affiliates.
- The manager waived base fees for May–September and waived Q4 incentive compensation and a portion of reimbursable expenses. Reported net management fees were $905,123.
- The audited financial statements received an unqualified opinion. However, management concluded disclosure controls were ineffective at year-end and identified material weaknesses in information-technology general controls and controls over risk ratings and the CECL reserve. Remediation was underway; the auditor did not attest to internal-control effectiveness.
Outlook, commentary, and principal risks
Management expects cannabis lending to remain its principal strategy and intends to grow the loan portfolio, with possible lending outside cannabis where returns fit its objectives. The company expected to need additional equity and/or debt funding as it expanded. No specific earnings or distribution guidance was provided.
- Federal cannabis prohibition: Cannabis remains illegal under U.S. federal law. Changes in enforcement, legislation, state rules, or licensing could impair borrowers, loan values, and the company’s business model.
- Collateral and recovery: The company cannot take title to real estate while it is used for cannabis operations under stated legal and listing constraints; cannabis licenses are generally non-transferable and inventory is not pledged. Foreclosure, regulatory approvals, delays, illiquidity, and specialized properties may reduce recoveries.
- Portfolio and funding risk: The business is new, concentrated in cannabis borrowers, and dependent on its external manager and access to capital. Competition, borrower defaults, interest-rate mismatches, refinancing needs, or unavailable financing could pressure returns and liquidity.
- Income and distributions: PIK interest and OID can be taxable or recorded as income before cash is received, potentially complicating REIT distribution requirements. REIT qualification and the Investment Company Act exemption require ongoing compliance.
- COVID-19 and other risks: Management said borrowers were permitted to operate and no COVID-related payment defaults or concessions had occurred through year-end, but broader economic effects remained uncertain. The company also disclosed it had no insurance coverage at the time described.
Important facts for investors to verify
- Reconcile the cash-flow figures: the audited statement reports $6.7 million of operating cash flow, while MD&A reports $5.7 million.
- Review the audited loan schedule and portfolio disclosures, including the $34.7 million of undrawn commitments, borrower concentration, collateral coverage, PIK/OID exposure, and the reported 18.6% YTM IRR, which is not a realized return.
- Assess the status and effectiveness of remediation for the two disclosed material weaknesses in financial reporting controls.
- Confirm compliance with revolving-facility covenants, REIT distribution and qualification requirements, and the Investment Company Act exemption as the portfolio grows.
- Evaluate the sustainability and cash funding of distributions, particularly given non-cash income and the company’s dependence on external capital.